A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders.

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Jul 2013

At a glance

  • Drugs Arbaclofen (Primary)
  • Indications Autistic disorder
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 May 2013 Primary endpoint 'Aberrant-Behavior-Checklist' has been met, according to Seaside Therapeutics media release.
    • 01 May 2013 Results presented at International Meeting for Autism Research (IMFAR), according to Seaside Therapeutics media release.
    • 01 May 2013 Status changed from active, no longer recruiting to completed, based on results reported in Seaside Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top